CBL — Control Bionics Income Statement
0.000.00%
- AU$14.14m
 - AU$13.98m
 - AU$7.04m
 
- 41
 - 41
 - 26
 - 27
 
Annual income statement for Control Bionics, fiscal year end - June 30th, AUD millions except per share, conversion factor applied.
2021 June 30th  | 2022 June 30th  | 2023 June 30th  | 2024 June 30th  | 2025 June 30th  | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M | 
| Source: | ARS | ARS | ARS | ARS | ARS | 
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS | 
| Status: | Final | Final | Final | Final | Final | 
| Revenue | |||||
| Total Revenue | 4.09 | 4.72 | 5.91 | 6.03 | 7.04 | 
| Cost of Revenue | |||||
| Gross Profit | 2.66 | 2.74 | 3.98 | 4.58 | 5.01 | 
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 7.67 | 10.8 | 11.5 | 11.9 | 13 | 
| Operating Profit | -3.58 | -6.08 | -5.61 | -5.86 | -5.93 | 
| Total Net Non Operating Interest Income / Expense | |||||
| Net Income Before Taxes | -3.55 | -6.1 | -5.63 | -5.91 | -6.11 | 
| Provision for Income Taxes | |||||
| Net Income After Taxes | -3.55 | -6.1 | -5.63 | -5.91 | -6.11 | 
| Net Income Before Extraordinary Items | |||||
| Net Income | -3.55 | -6.1 | -5.63 | -5.91 | -6.11 | 
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -3.55 | -6.1 | -5.63 | -5.91 | -6.11 | 
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.044 | -0.064 | -0.051 | -0.036 | -0.023 | 
| Dividends per Share |